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Rationale: Bronchoalveolar lavage fluid (BAL) from human lung
allograftsdemonstrates thepresenceof amultipotentmesenchymal
stromal cell population. However, the clinical relevance of this novel
cellular component of BAL and its association with bronchiolitis
obliterans syndrome (BOS), a diseasemarked by progressive airflow
limitation secondary to fibrotic obliteration of the small airways,
remains to be determined.
Objectives: In this study we investigate the association of number of
mesenchymal stromal cells in BAL with development of BOS in
human lung transplant recipients.
Methods:Mesenchymalcolony-formingunits (CFUs)werequantitated
in a cohort of 405 BAL samples obtained from 162 lung transplant
recipients. Poisson generalized estimating equations were used to
determine the predictors of BALmesenchymal CFU count.
Measurements and Main Results: Higher CFU counts were noted early
post-transplantation; time from transplant to BAL of greater than
3 months predicted 0.4-fold lower CFU counts (P 5 0.0001). BOS
diagnosis less than or equal to 365 days before BAL was associated
with a 2.11-fold higher CFU count (P 5 0.02). There were 2.62- and
2.70-fold higher CFU counts noted in the presence of histologic
diagnosis of bronchiolitis obliterans (P 5 0.05) and organizing
pneumonia (0.0003), respectively. In BAL samples obtained from
BOS-free patients greater than 6 months post-transplantation (n 5
173), higher mesenchymal CFU counts (>10) significantly predicted
BOS onset in both univariate (hazard ratio, 5.61; 95%CI, 3.03–10.38;
P, 0.0001) andmultivariate (hazard ratio, 5.02; 95%CI, 2.40–10.51;
P, 0.0001) Cox regression analysis.
Conclusions: Measurement of mesenchymal CFUs in the BAL provides
predictive information regarding future BOS onset.
Keywords: bronchiolitis obliterans syndrome; acute rejection; bron-
choalveolar lavage
Lung transplantation is the only viable option for many patients
with end-stage lung disease (1). However, long-term survival
after lung transplantation is limited by bronchiolitis obliterans
(BO), a fibroproliferative disease of the terminal airways marked
by infiltration with mesenchymal cells (2, 3). Progressive fibrotic
narrowing and obliterans of the airways leads to an irreversible,
relentless decline in lung function termed ‘‘bronchiolitis obliter-
ans syndrome’’ (BOS) (4). BOS is seen in 51% of transplant
recipients by 5.6 years and is the major cause of mortality after 1
year of transplantation (5). Early identification of this fibropro-
liferative process, allowing timely therapeutic interventions,
continues to be a major challenge in this field.
Bronchoalveolar lavage (BAL)offers aunique tool to sample the
internalmilieuof the lungand its cellular andmolecular components
have been evaluated to investigate markers and predictors of BOS
(6, 7). Proinflammatory cytokines (IL-8; regulated upon activation
normal T-cell expressed and secreted; monocyte chemoattractant
protein-1) (8–11), profibrotic growth factors (transforming growth
factor-b, platelet-derived growth factor) (10, 12), and markers of
extracellular matrix remodeling, such as matrix metalloproteases
(13), have been reported to be increased in the BAL fluid in pre-
sence of BOS. Among cellular components, an increase in pro-
portion of neutrophils is reported in BOS (9, 14, 15), but its
predictive ability is limited by its lack of specificity (16).
We have recently demonstrated that cells obtained from BAL
samples of human lung allografts, studied in culture in a plastic
adherent condition, demonstrate growth of distinct fibroblastoid
colony-formingunits (CFUs)ofmesenchymalprogenitor cellswith
multilineage differentiation potential (17). Mesenchymal cells are
the primary effector cells in fibroproliferation; however, the
association of this novel mesenchymal cell population in BAL
with the development of BOS has not been studied. In this study,
we quantitate mesenchymal CFUs in a large prospective cohort of
BAL samples obtained from lung transplant recipients and dem-
onstrate that an increase in number ofmesenchymalCFUs inBAL
predicts development of BOS. Some of the results of these studies
have been previously reported in the form of an abstract (18).
METHODS
Patient Population
Lung transplant recipients undergoing bronchoscopy at University of
Michigan were enrolled in a prospective trial. The study was approved
by the University of Michigan Institutional Review Board, and in-
formed consent was obtained before participation in the study.
Between January 2005 and February 2010, 561 BAL samples were
collected from193 lung transplant recipients.A total of 405BALsamples
from 162 patients, which could be maintained in culture for 14 days
allowingmesenchymal CFUmeasurement, were included in the analysis
(Figure 1). Compared with the 156 samples that were not included in the
analysis, these 405 samples included in the analysis were obtained at
a similar time post-transplant (P 5 0.10) and had a similar incidence of
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presence of BOS at the time of sampling (P 5 0.67). Similarly, no
differenceswere seen in the incidence of acute rejection (AR) (P5 0.82),
lymphocytic bronchitis (LB) (P5 0.71), and BO or organizing pneumo-
nia (P5 0.86) between the two groups. However, as expected, the BAL
samples with failure to maintain 2-week cultures had higher incidence of
positive bacterial (P5 0.002) and fungal cultures (P5 0.05).
BAL Mesenchymal CFU Assay
BAL samples were processed as previously described (17, 19). The
numbers of mesenchymal CFUs in BAL were measured using methods
similar to those described by Castro-Malaspina for bone marrow–
derived cells (20). Briefly, recovered BAL fluid was filtered through
a sterile strainer to remove noncellular particulate material, and the
cell pellet recovered by centrifugation at 1,000 rpm for 5 minutes. Two
million nucleated cells isolated from BAL were seeded in a 100-mm
cell culture dish and incubated at 378C in 5% CO2 / 95% air in medium
consisting of high-glucose Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA); 100
U/ml penicillin/streptomycin (Invitrogen); and 0.5% fungizone (Invi-
trogen). Medium was changed every 3 days. Single separated fibro-
blastoid colonies are identified as early as 7 days after initial plating.
Colonies were counted between Days 14 and 21 after initial plating.
Characterization of Mesenchymal CFUs
Mesenchymal CFUs from BAL of lung transplant recipients were
expanded in culture and further characterized using methodology as
previously described (17). BAL samples from five patients from each
group (normal, evidence of AR on histology, and evidence of BOS on
physiology) were studied. The cell surface phenotype of culture-
expanded cells was analyzed bymultiparameter flow cytometric analyses
(fluorescence-activated cell sorter). Briefly, cells were trypsinized at
passage 2; aliquotted at a concentration of 0.5 3 106 cells per milliliter;
and stained for 30minuteswith either conjugated specific antibodies (BD
biosciences, San Jose, CA) or isotype-matched control mouse IgGs at
recommended concentration. Labeled cells were washed twice; resus-
pended in fluorescence-activated cell sorter buffer; and analyzed on
fluorescence-activated cell sorter Calibur flow cytometer using the
CellQuest software program (Becton Dickinson, Franklin Lakes, NJ).
To investigate multilineage differentiation potential, adipogenic and
osteogenic differentiation was performed on culture-expanded cells as
previously described (17). For adipogenic differentiation, confluent cells
cultures in a 24-well plate were treated with adipogenic differentiation
medium containing 1026M dexamethasone, 0.5 mM isobutylmethylxan-
thine, 10 mg/ml insulin, and 200 mM indomethacin in Dulbecco’s
modifiedEaglemediumhigh glucosemedia (0.5ml per well). At 3 weeks
cellswerefixedwith 10%formaldehyde (Fisher Scientific, FairLane,NJ)
and incubated with fresh oil red O for 1 hour at room temperature; lipid
droplets were visualized and photographed. Osteogenic differentiation
was induced by incubating the cells with 1028M dexamethasone, 0.2mM
ascorbic acid, and 10mM b-glycerophosphate in basal medium. After 21
days, cells were fixed and incubated with freshly made 2% alizarin red
stain, pH 4.2 for 3 minutes. All reagents, unless specified, were from
Sigma (St. Louis, MO). mRNA was isolated and real-time polymerase
chain reaction performed as previously described (17).
Clinical Variables
The indication for bronchoscopy was defined as surveillance if it was
performed routinely to rule out AR. Nonsurveillance bronchoscopies
were performed when clinically indicated for such factors as dyspnea,
decrement in lung function, or follow-up of previous episodes of AR.
Transbronchial biopsies obtained at the time of BAL were examined
according to established criteria (21). AR was defined as biopsy score of
greater than or equal to A1. LB was defined as biopsy score of greater
than or equal to B1. BOSwas defined by physiologic testing according to
the International Society of Heart and Lung Transplantation guidelines
(4). Information on bacterial, fungal, and viral cultures was available on
all BAL samples. Positive cytomegalovirus (CMV) was defined as CMV
detection in BAL by shell vial (early antigen detection) or culture.
Information on relative proportion of neutrophils, lymphocytes, macro-
phages, and eosinophils in theBALwas obtained from the results of fluid
cell differential performed in the clinical pathology laboratory at the
University of Michigan.
Statistical Analyses
The Wilcoxon signed-rank test was used to compare pair-wise differ-
ences in continuousCFU-F counts between aliquots from the sameBAL
sample. A one sample t test was used to test that CFU-F between serial
dilutions decreased by 50% on average. Wilcoxon rank-sum tests were
used to compare CFU-F counts between cases and controls at various
time-points post–lung transplantation. Poisson generalized estimating
equations (GEE)were used to determinewhich clinical variables predict
CFU-F counts in BAL samples. GEE, a well-established strategy for
analysis of correlated data (22), was used becausemultiple samples were
obtained at different time points from the same subjects.GEEswere also
used to determine association of various BAL cell populations (percent
neutrophils, percentmacrophages, and percent lymphocytes) with CFU-
F counts. Time to BOS was modeled using Cox proportional hazards
models with robust variance estimation (23, 24) used to account for
patients contributing more than one event history from various BAL
measurements. CFU group-specific adjusted times to BOS plots for the
average patient profile were taken from corresponding Cox models.
RESULTS
Patient Population
A total of 405 BAL samples obtained from 162 lung transplant
recipients comprised the study cohort. The patient population
included 71 females and 91 males with a mean age of 51 years
(range, 21–69 yr) at the time of transplantation.Major indications
for transplantation included emphysema (n 5 69); idiopathic
pulmonary fibrosis (IPF) (n 5 50); cystic fibrosis (n 5 20); and
other diagnoses (n 5 23). Clinical variables at the time of BAL
and the number of patients contributing these data in the study
cohort are displayed in Table 1. Histologic information from
concurrently performed trans-bronchial biopsieswas available on
372 BAL samples.
Quantitation and Characterization of Mesenchymal CFUs in
the BAL Obtained from Lung Transplant Recipients
The number of mesenchymal CFUs in the BAL was quantitated
as described in theMETHODS section. CFUcounts per 23 106 cells
plated in a 100-mm dish were reported. To determine that the
Figure 1. CONSORT diagram illustrating the selection of patients in-
cluded in the data analysis. BAL 5 bronchoalveolar lavage; GEE 5
generalized estimating equation; BOS5 bronchiolitis obliterans syndrome.
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quantitation technique is valid, cells obtained from 15 BAL
samples were plated in duplicate (2 3 106 million cells per dish,
two separate 100-mm dishes). Mesenchymal CFU counts were
obtained for each dish in a given patient. There were no
statistically significant differences between aliquots (Wilcoxon
signed-rank test; P5 0.94). Further serial twofold dilutions were
performed on five BAL samples. An average of 51% decrease in
CFU counts (range, 40–60%) was noted between serial dilutions.
The decrease is not significantly different from 50% according to
one sample t test (P5 0.44). These analyses show reproducibility
betweenmeasures of CFUcount fromaBAL sample and support
the quantitative nature of the CFU assay.
Mesenchymal CFUs from representative BAL samples de-
rived from lung transplant recipients were culture expanded and
recharacterized. Similar to what has been previously described
for multipotent mesenchymal stromal cells (17, 25, 26), culture-
expanded CFUs from BAL of patients in all groups (normal,
AR, and BOS) demonstrated expression of CD44, CD105,
CD73, and CD90 (Figure 2), and lacked expression of CD45
and CD34 (data not shown). Multilineage differentiation to
adipocytic and osteocytic lineages was demonstrable in all cell
lines tested (Figure 3).
Predictors of Mesenchymal CFUs in the BAL
Mesenchymal CFU counts in the BAL fluid obtained from lung
transplant recipients demonstrated significant variability (range,
0–90; mean, 10.34; SD, 15.41). The distribution of mesenchymal
CFU counts in the BAL samples is shown in Figure 4.
Poisson GEEs were used to determine the clinical variables
that predict mesenchymal CFU counts in BAL samples. Time
from transplantation, presence of BOS, and a histologic diagnosis
of BO or organizing pneumonia were significant predictors of
number of mesenchymal CFUs in the BAL (Table 2). Time post-
transplant of greater than 90 days was associated with a 0.40-fold
lower CFU count (95% confidence interval [CI], 0.30–0.53; P ,
0.0001) in the BAL. CFU counts of 2.62- and 2.70-fold higher
were noted in the presence of histologic diagnosis of bronchiolitis
obliterans (95%CI, 1.00–6.92; P5 0.05) and histologic diagnosis
of organizing pneumonia (95% CI, 1.57–4.65; P 5 0.0003),
respectively, on concurrent biopsies. Higher CFU counts were
also noted inBAL samples obtained less than or equal to 365 days
after BOS onset (early post-BOS) (2.11-fold increase; 95% CI,
1.10–4.03; P5 0.02). Other histologic diagnoses, presence of late
post-BOS (time from BOS to BAL.365 d), presence of positive
bacterial cultures, CMV positivity, indication for bronchoscopy,
and pretransplant diagnosis did not significantly predict number
of mesenchymal CFUs in the BAL.
Analysis of mean CFU counts over time post-transplantation
demonstrated a bimodal distribution with higher mean mesen-
chymal CFUs in BALs obtained at time post-transplant of less
than or equal to 3 months and greater than or equal to 24 months
(Figure 5). The late increase was not seen when BAL samples
obtained in presence of BOS (n5 46) or within 6 months of BOS
onset (n 5 36) were excluded.
Cell count and differential were available on 374 BAL
samples. No association was noted between mesenchymal CFU
counts and relative proportion of other cellular populations
(percent neutrophil, percent lymphocytes, and percent macro-
phage; P 5 0.30, 0.61, and 0.42, respectively).
Increased Numbers of Mesenchymal CFUs in BAL
as a Predictor of BOS Onset
Next, we investigated if increased mesenchymal CFU counts in
BAL samples can predict future development of BOS. Patients
were followed for development of BOS until February 12, 2010.
For this analysis BAL samples that were obtained from patients
who were greater than 6 months post–lung transplantation and
had no evidence of BOS at the time of BAL were used (n5 246).
A total of 73 BAL had missing CFU values. No difference was
seen in time to BOS onset from BAL between the cohort used in
the analysis (173 BAL from 107 patients) versus the cohort with
missing CFU values (P 5 0.35).
Mesenchymal CFU count in BAL significantly predicted
subsequent BOS development (hazard ratio [HR], 1.04 for every
one mesenchymal CFU increase in BAL; 95%CI, 1.03–1.06; P,
0.0001). For the purpose of clinical use, mesenchymal CFU was
also studied as a categorical variable. High CFU count was
defined as CFU greater than or equal to 10 per 23 106 nucleated
cells. This threshold was based on results shown in Figure 5 and
estimated means from parameter estimates obtained from the
GEE model shown in Table 2. High CFU count (CFU >10 in
BAL 6 mo after transplantation) was found to be a significant
predictor of subsequent BOS development (HR, 5.61; 95% CI,
3.03–10.38;P, 0.0001).Kaplan-Meier curves shown inFigure 6A
demonstrate time to BOS in lung transplant recipients grouped
by number of CFU-Fs in BAL. Median time to development of
BOS from a BAL sample demonstrating CFU-F count greater
than or equal to 10 was 370 days.
In multivariate analysis (Table 3), after adjusting for pres-
ence of AR, LB, sex, type of transplantation (single vs. bi-
lateral), pretransplant diagnosis (IPF, emphysema, or others)
and time post-transplantation, high CFU-F count remained
a significant predictor of BOS onset (HR, 5.02; 95% CI, 2.40–
10.51; P , 0.0001). Cox model-based survival estimates are
shown for an average patient profile in Figure 6B.
Of the 24 patients who developed BOS during the course of
follow-up, 17 patients were initially diagnosed as BOS stage 1,
two as BOS stage 2, and five as BOS stage 3. At 6 months after
BOS onset, 12 patients progressed to higher grades of BOS, and
3 died of BOS-related complications. Eight patients were in the
same stage of BOS at 6 months and improvement of BOS grade
was noted in four patients.
TABLE 1. CHARACTERISTICS OF BRONCHOALVEOLAR LAVAGE
SAMPLES*
Clinical Variable
N (number of patients
contributing samples)
Indication for bronchoscopy
Surveillance 257 (120)
Nonsurveillance 148 (94)
Time from transplant to BAL
0–3 mo 110 (78)
3–6 mo 76 (63)
6 mo–1 yr 77 (64)
1–2 yr 67 (51)
.2 yr 75 (59)
Biopsy at the time of BAL
Acute rejection (>A1) 52 (43)
Lymphocytic bronchitis (>B1) 26 (25)
Bronchiolitis obliterans 4 (4)
Organizing pneumonia 8 (8)
Biopsy not performed 33 (29)
BOS at the time of BAL
BOS-free at the time of BAL 359 (145)
Early post-BOS (time from BOS to BAL ,365 d) 29 (19)
Late post-BOS (time from BOS to BAL >365 d) 17 (14)
Microbiology cultures from BAL
Positive bacterial cultures 51 (36)
Positive cytomegalovirus viral cultures 17 (14)
Positive respiratory viral cultures 9 (9)
Definition of abbreviations: BAL 5 bronchoalveolar lavage; BOS 5 bronchiolitis
obliterans syndrome.
* 405 samples from 162 patients.
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DISCUSSION
In this study we examined the relationship between a novel
cellular component of BAL (number of mesenchymal stem cells
[MSCs]) and development of BOS in human lung transplant
recipients. We demonstrate that presence of BOS is associated
with an increase in mesenchymal CFU counts in BAL fluid.
Histologic diagnosis of BO or organizing pneumonia on con-
current trans-bronchial biopsies also predicted higher mesen-
chymal CFU counts in the BAL. Importantly, increased number
of mesenchymal CFUs in BAL fluid was found to be a significant
predictor of future BOS onset. Together, these data identify
a novel cellular marker of chronic allograft rejection in human
lung transplant recipients.
Quantitation of BAL mesenchymal CFU counts and its
correlation with clinical variables in a large cohort of lung
transplant recipients provides the first documentation of clinical
predictors of MSC population in the BAL. Predictors of higher
mesenchymal CFU counts in the BAL included diagnosis of BO
or organizing pneumonia on histology, presence of BOS on
pulmonary function testing, and time post-transplant less than
or equal to 90 days. A very strong association was noted between
number of mesenchymal CFUs in the BAL and histologic
evidence of organizing pneumonia. Organizing pneumonia,
a condition marked by presence of mesenchymal cells in the
alveoli, can be commonly diagnosed by transbronchial biopsies.
However, transbronchial biopsies have a low sensitivity for
diagnosing BO, the histologic manifestation of BOS (27). A
surrogate for amesenchymal proliferative process in theBALcan
have a potential role in differentiating a fall in FEV1 from BO
versus other confounding factors, such as hyperinflation or
bronchial stenosis, hence identifying a more homogeneous BOS
population. Higher BALCFU counts were noted in the presence
of histologic diagnosis of BO in our cohort. However, because of
small numbers of cases with evidence of BO on biopsies, further
studies validating this finding and establishing the clinical use of
this marker in diagnosing BO in conjunction with clinical and
physiologic parameters are warranted.
Figure 2. Flow cytometric
analysis of cell surface markers
on culture-expanded mesen-
chymal CFUs. Bronchoalveolar
lavage (BAL) CFUs from lung
transplant recipients (control,
acute rejection [AR], and
bronchiolitis obliterans syn-
drome [BOS]) were expanded
in culture and immunostained
for CD44, CD90, CD73, and
CD105 surface markers with
specific mAbs. Cells from the
three groups were found to be
predominantly positive for the
surface markers studied. All
histograms demonstrate spe-
cific mAbs in black and control
isotype-specific IgGs in gray.
The percentage of positive
cells relative to the total num-
ber of cells analyzed (mean 6
SD) is shown above the re-
spective histograms. n 5 5
individual patients in each
group.
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Diagnosis of BOS was found to be a significant predictor of
MSC population in the allograft with twofold higher mesenchy-
mal CFUs noted in BAL samples obtained with a year of BOS
onset. This association was not seen in BAL samples obtained
after a year of BOS onset. Study of course of FEV1 after BOS
onset has demonstrated that maximal decline in FEV1 occurs
within the first year afterBOSonset (28). It can be speculated that
the early time period after BOS onset marks a period of maximal
fibroproliferation and hence this association with high mesen-
chymalCFUs.Thepresent studywas not powered to investigate if
changes in CFU count after BOS onset correlate with the course
of FEV1 in these patients.A future prospectivemulticentric study
is needed to investigate the prognostic ability of longitudinal
changes in BAL CFU counts in patients with BOS.
Analysis of time post-transplant and CFU count demon-
strated a very interesting bimodal distribution with higher mean
mesenchymal CFU counts noted in BAL samples first within 3
months and then later after 24 months of lung transplantation.
The presence of elevated MSC population early post-transplant,
a period marked by intense cellular response to graft injury, is
similar to what has been described for other cellular populations
in the BAL (7). Elevated total cell count and neutrophils are
seen in BAL during the first 3 months after lung transplantation
(7). Whether this cellular response, in the form of increased
mesenchymal cells accumulation in the first 3 months after lung
transplantation, varies with the degree of ischemia reperfusion
injury remains to be determined. The increase in MSC pop-
ulation in BAL at later time after lung transplantation was
associated predominantly with development of BOS.
Analysis of a prospective cohort of BOS-free patients dem-
onstrated that higher number of MSCs in BAL 6 months of lung
transplantation significantly predicted future BOS onset. Mesen-
chymal CFU counts greater than or equal to 10 in BAL samples
were associated with an approximately fivefold higher hazard of
developing BOS. Predicting BOS early, before clinical compro-
mise, is critical for instituting therapeuticmodalities to prevent or
Figure 3. Multilineage differentiation potential
of culture-expanded bronchoalveolar lavage
(BAL) mesenchymal CFUs. (A) Cell lines gener-
ated from BAL CFUs of control, acute rejection
(AR), or bronchiolitis obliterans syndrome
(BOS) patients (n 5 5 in each group) were
investigated for the in vitro multilineage differ-
entiation capacity. Accumulation of lipid drop-
lets (indicating adipocytic differentiation) was
demonstrated by staining with oil red O in
treated cells. Osteocytic differentiation was in-
dicated by calcium deposition as demonstrated
by alizarin red staining (red color) in treated
cells. No staining was observed in control un-
treated cells. (B) Real-time polymerase chain
reaction was performed to analyze the expres-
sion of specific adipogenic and osteogenic re-
lated mRNAs under inductive culture
conditions. Relative expression of PPAR-a
mRNA (indicative of adipogenic activity) and
osteopontin mRNA (indicative of osteogenic
activity) are shown in control and treated
conditions.
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delay BOS onset. Information obtained from bronchoscopy,
either BAL or transbronchial biopsies, has been evaluated to
identify a simple predictor or biomarker of BOS. In retrospective
analysis, diagnosis of a single or multiple episodes of AR and LB
on transbronchial biopsies has been associatedwithBOS (29–33).
Our analyses are restricted to patients who are already 6 months
out from transplant and evaluated time to BOS onset from
individual BAL. Similarly, another major difference in our
approach was that we focused on the predictive ability of the
current BAL and not cumulative information from all previous
BALs. Thus, a patient with no AR at the time of the bronchos-
copy performed as a part of this study might have had AR in the
past. These differences could explain the lack of association of
AR or LB with BOS in our model.
No significant association was seen in our cohort between
mesenchymal CFUs in the BAL and positive CMV cultures.
CMV infection and disease are considered a possible risk factor
for development of BOS (4). It is important to note that in our
cohort of patients with positive CMV cultures only one case had
evidence of true CMV disease as shown by cytopathic changes
on transbronchial biopsies. Thus, this study cannot comment on
the association of mesenchymal CFUs and CMV pneumonitis.
Similarly, although no correlation was seen between number of
mesenchymal CFUs in BAL and positive bacterial cultures in
the cohort from which CFU count could be obtained, there was
increased incidence of positive bacterial culture in BAL with
missing CFU data. This suggests that measuring the MSC
population in the BAL by CFU count has limited predictability
in the patient population with positive bacterial culture because
this population is at increased risk of missing CFU data.
In multivariate analysis, after adjusting for presence of AR,
LB, CMV, sex, type of transplantation (single vs. bilateral),
pretransplant diagnosis (IPF, emphysema, or others), and time
post-transplantation, high CFU count remained a significant
predictor of BOS onset (HR, 4.73; 95% CI, 2.22–10.10; P ,
0.0001). Although this ability of MSC numbers in the BAL to
predict BOS onset suggests a potential for using this informa-
tion in the clinical arena, a major limitation in our methodology
of MSC quantitation is that it requires culturing BAL cells in
plastic adherent conditions for 2 weeks. This technique, other
than being time consuming, also leads to significant number of
missing counts. Future investigation of a marker of MSCs that
can be analyzed in a high-throughput manner is required to
translate these finding to the clinical arena.
Figure 4. Distribution of mesenchymal CFU counts in bronchoalveolar
lavage (BAL) samples obtained from lung transplant recipients. Num-
bers of mesenchymal CFUs in the BAL was quantitated by culturing BAL
cells in plastic adherent condition. CFU counts per 2 3 106 cells plated
in a 100-mm dish were reported (n 5 405).
TABLE 2. MULTIVARIATE ANALYSIS OF THE PREDICTORS OF
MESENCHYMAL CFU COUNTS IN BRONCHOALVEOLAR LAVAGE
FLUID OF HUMAN LUNG TRANSPLANT RECIPIENTS (N 5 372)
Variable
Estimate (95%
confidence interval)* P Value†
Time post-transplant .90 d 0.40 (0.30–0.53) ,0.0001‡
Early post-BOS (BOS to BAL <365 d) 2.11 (1.10–4.03) 0.02‡
Late post-BOS (BOS to BAL .365 d) 1.47 (0.70–3.07) 0.31
Acute rejection (>A1) 0.95 (0.69–1.30) 0.75
Lymphocytic bronchitis (>B1) 0.80 (0.49–1.31) 0.38
Bronchiolitis obliterans 2.62 (1.00–6.92) 0.05‡
Organizing pneumonia 2.70 (1.57–4.65) 0.0003‡
Positive bacterial cultures 1.31 (0.74–2.32) 0.35
Positive cytomegalovirus cultures 0.62 (0.30–1.28) 0.20
Other virus 1.26 (0.47–3.37) 0.65
Nonsurveillance bronchoscopy (vs. surveillance) 1.08 (0.80–1.46) 0.62
Pretransplant diagnosis
Idiopathic pulmonary fibrosis 0.70 (0.42–1.16) 0.16
Emphysema 0.81 (0.46–1.43) 0.47
Cystic fibrosis 0.70 (0.38–1.29) 0.26
Others 1.00x NAx
Definition of abbreviations: BAL 5 bronchoalveolar lavage; BOS 5 bronchiolitis
obliterans syndrome.
* Estimates indicate the multiplicative increase or decrease in expected CFU-F
count according to the factor being true versus false, other factors held constant.
† P values generated from multivariate generalized estimating equation models
accounting for correlation within patients.
‡ P , 0.05.
x Reference population.
Figure 5. Relationship of mesenchymal CFU count bronchoalveolar
lavage (BAL) samples and time post-lung transplantation. Mean CFU
count over various time periods post-lung transplantation are demon-
strated in all BAL samples (blue diamonds; n 5 405). A bimodal
distribution with higher mean mesenchymal CFUs in BALs obtained
at time post-transplant of less than or equal to 3 months and greater
than or equal to 24 months was seen. The late increase was not seen
when BAL samples obtained in presence of BOS (n 5 46) or within 6
months of BOS onset (n 5 36) were excluded (red squares).
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The study population in this investigation was limited to BAL
samples from lung transplant recipients in whom CFU assay
could be performed. Hence, this study is applicable only to this
population and cannot comment on the patients with missing
CFU data in the BAL. The present analyses suggest that time to
onset of BOS is similar for the group with missing BOS count
versus the cohort with known CFU count. However, further
follow-up is needed to evaluate definitely whether ‘‘missing
CFU’’ is a distinct biologic cohort. An evaluation of this pop-
ulation requires the performance of a prospective study with
BAL samples obtained at regular intervals. In such a study, the
effect of longitudinal changes in mesenchymal CFUs can be
investigated as a predictor of BOS onset and progression.
Although this study provides the first evidence for a dynamic
change in MSC numbers in a transplanted lung, the role of
endogenous MSCs in adaptive and maladaptive repair responses
in the lung remains unclear.MSCshave strong immunomodulating
properties (34, 35) and exogenous administration of bonemarrow–
derived MSCs has been shown to ameliorate injury in animal lung
injury models (36–38).We have recently demonstrated thatMSCs
derived from human lung allografts inhibit T cells in vitro via
secretion of soluble mediators (19). However, MSCs can also play
an important role in tissue fibrosis. Bone marrow–derived MSCs
can differentiate into myofibroblasts in vitro (39, 40) and mesen-
chymal progenitor cells have been shown to participate in fibrotic
responses (41, 42). These observations suggest thatMSCs can have
divergent effects in acute and chronic injury scenarios and their
role in human diseases should be investigated.Our study is the first
study to investigate endogenousMSCs in human injury. Increased
numbersof lung-residentMSCswerenotedearlypost-transplant in
patients with both favorable and unfavorable long-term outcomes
demonstrating that these cells are not associated with fibrosis
during acute injury. However, increased numbers at later time
points post–lung transplantation were associated with develop-
ment of BOS. On the basis of these observations it can be
speculated that lung-resident MSCs, which are recruited in re-
sponse to injury, can bemodulated by the presence of a profibrotic
milieu and potentially contribute to fibrogenesis. Further work is
needed to elucidate the role of these mesenchymal precursor cells
in the pathogenesis of BOS.
In summary, this study demonstrates that an increase in
mesenchymal CFU counts in BAL is seen in association with
BO/BOS and is a strong predictor of future BOS onset. Because
BAL is routinely performed in lung transplant recipients, evalu-
ation of this potential marker of fibroproliferative responses in
the lung can provide important prognostic information regarding
BOS onset and course. Further research is required to determine
the role of serial measurements of mesenchymal CFUs in the
follow-upof patientswithBOSandwhetherCFUnumbers canbe
used as biomarkers of disease activity and response.
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Figure 6. Mesenchymal CFUs in the bronchoalveolar lavage (BAL) as
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transplant recipients. (A) Kaplan-Meier curve demonstrating time to
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specific adjusted time to BOS plots based on survival estimates obtained
using hazards estimated with Cox models adjusted for average patient
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5 10%; probability of pretransplant diagnosis of idiopathic pulmonary
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TABLE 3. MULTIVARIABLE PROPORTIONAL-HAZARDS ANALYSIS
OF THE RISK OF BOS ONSET BY VARIABLES PRESENT AT THE
TIME OF BAL
Variable
Hazard
Ratio
95% CI
(lower)
95% CI
(upper)
P
Value
Mesenchymal CFU count >10 5.02 2.40 10.51 ,0.0001
Time post-transplant, yr 1.04 0.84 1.30 0.71
Acute rejection (>A1) 1.22 0.38 3.87 0.74
Lymphocytic bronchitis (>B1) 0.72 0.35 1.48 0.37
Cytomegalovirus 0.94 0.31 2.86 0.91
Pretransplant diagnosis
Idiopathic pulmonary fibrosis 0.45 0.07 2.90 0.40
Emphysema 0.77 0.16 3.81 0.75
Cystic fibrosis 0.80 0.14 4.58 0.80
Others ref Ref ref NA
Type of transplant, bilateral 1.33 0.54 3.26 0.53
Sex, male 1.54 0.68 3.44 0.30
Definition of abbreviations: BAL 5 bronchoalveolar lavage; BOS 5 bronchiolitis
obliterans syndrome; CI 5 confidence interval.
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